Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in 'Unfit' Hormone-Refractory Patients Previously Treated With Docetaxel

Trial Profile

Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in 'Unfit' Hormone-Refractory Patients Previously Treated With Docetaxel

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2017 Results assessing safety and efficacy published in the European Journal of Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top